425 related articles for article (PubMed ID: 27095739)
1. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
[TBL] [Abstract][Full Text] [Related]
2. Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.
Tafe LJ; Pierce KJ; Peterson JD; de Abreu F; Memoli VA; Black CC; Pettus JR; Marotti JD; Gutmann EJ; Liu X; Shirai K; Dragnev KH; Amos CI; Tsongalis GJ
Neoplasia; 2016 Sep; 18(9):577-83. PubMed ID: 27659017
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
[TBL] [Abstract][Full Text] [Related]
4. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Akahane T; Kanomata N; Harada O; Yamashita T; Kurebayashi J; Tanimoto A; Moriya T
BMC Cancer; 2020 Oct; 20(1):944. PubMed ID: 33004031
[TBL] [Abstract][Full Text] [Related]
6. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
[TBL] [Abstract][Full Text] [Related]
8. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.
Rothé F; Laes JF; Lambrechts D; Smeets D; Vincent D; Maetens M; Fumagalli D; Michiels S; Drisis S; Moerman C; Detiffe JP; Larsimont D; Awada A; Piccart M; Sotiriou C; Ignatiadis M
Ann Oncol; 2014 Oct; 25(10):1959-1965. PubMed ID: 25185240
[TBL] [Abstract][Full Text] [Related]
9. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer.
Furuki H; Yamada T; Takahashi G; Iwai T; Koizumi M; Shinji S; Yokoyama Y; Takeda K; Taniai N; Uchida E
Eur J Surg Oncol; 2018 Jul; 44(7):975-982. PubMed ID: 29452859
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
[TBL] [Abstract][Full Text] [Related]
12. Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential.
Gleeson FC; Kipp BR; Voss JS; Campion MB; Minot DM; Tu ZJ; Klee EW; Graham RP; Lazaridis KN; Henry MR; Levy MJ
Gastrointest Endosc; 2015 Sep; 82(3):550-6.e1. PubMed ID: 25887718
[TBL] [Abstract][Full Text] [Related]
13. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
14. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
15. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
[TBL] [Abstract][Full Text] [Related]
16. Effective quality management practices in routine clinical next-generation sequencing.
de Abreu FB; Peterson JD; Amos CI; Wells WA; Tsongalis GJ
Clin Chem Lab Med; 2016 May; 54(5):761-71. PubMed ID: 26872315
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
18. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.
Goswami RS; Patel KP; Singh RR; Meric-Bernstam F; Kopetz ES; Subbiah V; Alvarez RH; Davies MA; Jabbar KJ; Roy-Chowdhuri S; Lazar AJ; Medeiros LJ; Broaddus RR; Luthra R; Routbort MJ
Clin Cancer Res; 2015 Jun; 21(11):2644-51. PubMed ID: 25695693
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
[TBL] [Abstract][Full Text] [Related]
20. Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung.
McCullar B; Pandey M; Yaghmour G; Hare F; Patel K; Stein K; Feldman R; Chandler JC; Martin MG
Breast Cancer Res Treat; 2016 Jul; 158(1):195-202. PubMed ID: 27329168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
